Syndax Pharmaceuticals, Inc.

Equities

SNDX

US87164F1057

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 10:24:55 2024-03-28 am EDT 5-day change 1st Jan Change
23 USD -0.33% Intraday chart for Syndax Pharmaceuticals, Inc. -0.13% +5.74%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia CI
Syndax Pharmaceuticals Says FDA Grants Priority Review to New Drug Application for Acute Leukemia Treatment MT
Syndax Says Revumenib NDA Granted FDA Priority Review DJ
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia CI
JPMorgan Raises Price Target on Syndax Pharmaceuticals to $34 From $31, Maintains Overweight Rating MT
Sector Update: Health Care Stocks Rise Monday Afternoon MT
Syndax Pharmaceuticals Names Steven Closter Chief Commercial Officer MT
Syndax Pharmaceuticals, Inc. Announces Executive Changes CI
Transcript : Syndax Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 08:30 AM
Transcript : Syndax Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 27, 2024
Syndax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Syndax Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Transcript : Syndax Pharmaceuticals, Inc. Presents at Citi 2024 Virtual Oncology Leadership Summit, Feb-21-2024 11:00 AM
Certain Restricted Stock Units of Syndax Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-FEB-2024. CI
Certain Stock Options of Syndax Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-FEB-2024. CI
Certain Pre-Funded Warrants of Syndax Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-FEB-2024. CI
Certain Common Stock of Syndax Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-FEB-2024. CI
North American Morning Briefing : Stock Futures -2- DJ
Scotiabank Downgrades Syndax Pharmaceuticals to Sector Perform From Sector Outperform, Cuts Price Target to $23 From $36 MT
Transcript : Syndax Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 05:15 PM
Syndax Pharmaceuticals Jumps in Premarket Ahead of CEO Presentation at J.P. Morgan Healthcare Conference on Monday MT
Syndax Pharmaceuticals Raises $230 Million in Gross Proceeds From Common Stock Offering MT
Correction: Syndax Pharmaceuticals Prices Public Offering at $18.50 per Share MT
Sector Update: Health Care Stocks Mixed Pre-Bell Friday MT
Syndax Pharmaceuticals Price IPO at $18.50 per Share MT
Chart Syndax Pharmaceuticals, Inc.
More charts
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing a pipeline of cancer therapies. The Company's lead product candidates include SNDX-5613 (revumenib) and SNDX-6352 (axatilimab). It is focused on developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, also known as mixed lineage leukemia rearranged (MLLr), acute leukemias including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), and nucleophosmin 1 (NPM1) mutant AML. Its axatilimab, is a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis (IPF). Its products candidate also includes entinostat, an oral, small molecule and Class I histone deacetylases (HDAC) inhibitor that has direct effects on both cancer cells and immune regulatory cells.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
23.07 USD
Average target price
35.17 USD
Spread / Average Target
+52.43%
Consensus
  1. Stock
  2. Equities
  3. Stock Syndax Pharmaceuticals, Inc. - Nasdaq
  4. News Syndax Pharmaceuticals, Inc.
  5. Syndax Pharmaceuticals' : Finance Chief Daphne Karydas to Step Down